

Product name: 25% Natural CBD+CBDA in MCT

Product code: CBD-OIL-25-NAT-MCT

	ION 1: Identification any/undertaking	of the	substa	nc	e/mixture and of the			
1.1.	Product identifier							
	Trade name:	NATUI	RAL oil C	3D+	-CBDA 25 % in MCT oil			
	Main component:	Cannal	bis sativa	extı	ract, MCT oil			
	Constituent name:	2-[(1R,	6R)-3-me	thy	l-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-			
	Constituent name.	pentyll	pentylbenzene-1,3-diol Cannabidiol, CBD					
	Chemical name:	/	/					
1.2.	Relevant identified uses	of the s	ubstance	or ı	mixture and uses advised against			
	Uses:			In	dustrial use; Intermediate			
	Uses advised against:			Вι	ılk product			
	Reason why uses advise	ed agains	st:	N	one			
1.3.	Details of the supplier of	of the saf	ety data s	shee	et			
	Supplier:		CBD Oil	Eu	rope			
	Address:		Voltawe	g 1	1D, 4382 NG Vlissingen, the Netherlands			
	Telephone number:		+31 (0)	31 (0) 64 0690002				
	e-mail of competent pe	rson:	info@cbdoileurope.com					
	Production:		Croatia					
	Brand:		NATUR	AL d	oil			
1.4.	Emergency telephone n	umber						
	National Protection and Directorate:	Rescue	escue (EU) 112		(EU) 112			
	Medical information:			SZT (CRO) +385 98 405 636				
	Other information:							
SECT	ION 2. Hazards iden	tificati	on					
2.1.	Classification of the sub	stance c	r mixture					
2.1.1.	Classification according	to Regu	lation (EC	:) N	o 1272/2008 (CLP)			
	Hazard pictograms							
	GHS08							
	Signal word:		War	nin	g			
2.1.2.	Additional information		<u> </u>					
2.2.	Label elements/Labellin	g accord	ling to Re	gula	ation (EC) No 1272/2008 [CLP]			

Version 1





Product code: CBD-OIL-25-NAT-MCT

	Product identification:			en- Car	(1R,6R)-3-methyl-6-(prop- 1-yl]-5-pentylbenzene-1, nnabidiol, CBD S:13956-29-1		
	Cosmetic Ir	ngredients Datab	ase (EU)	Cannabidiol, CBD			
	CAS No. of the mixture:				t assigned		
	EC No. of the mixture:				t assigned		
	HS code of	the mixture:		130	02 19 (Vegetable saps and	extracts)	
	Hazard stat	tement:					
			H361	Sus chi	spected of damaging fertil ld.	ity or the unborn	
	Precaution	ary statement:					
			P201	Ob	tain special instructions be	efore use.	
			P202	3	not handle until all safety en read and understood	precautions have	
			P233	Kee	ep container tightly closed	l	
			P264	Wash skin thoroughly after handling			
			P273	Avoid release to the environment			
	P280				Wear protective gloves/ eye protection /face protection		
			P370	In case of fire, use chemical foam, carbon dioxide			
2.3.	Other haza						
		e does not meet of Regulation (E0			T or vPvB substances in ad [REACH].	ccordance with	
SECT	ION 3. Con	nposition/inf	ormation o	n in	gredients		
CAS	No./EC No. ex number	REACH Registration No	Conc. % content (or range)		Identification name	Classification according to Regulation (EC) No 1272/2008 (CLP)	
	None	None	25,00-26,6	7	Cannabis sativa extract - Natural	Not classified	
65381-0 EC: 277-	CAS: 73398-61-5/ 65381-09-1 EC: 277-452-2/ 265-724-3		73,33-75,00		MCT oil	Not classified	
SECT	ION 4. Firs	t aid measur	es				
4.1.							
1. 2.				ngest	alth problems after prodution) consult a medical of t.		

Version 1





Product code: CBD-OIL-25-NAT-MCT

	Hazardous combustion products:  monoxide and carbon dioxide (immediately toxic gase Inhalation of hazardous degradation products (such as small so particles from pyrolysis) may cause serious health damage (ful poisoning).						
		Smoke is produced in a fire, with potential production of carbon monoxide and carbon dioxide (immediately toxic gases).					
5.2.	Special hazards arising from	m the substance or mixture					
	Unsuitable extinguishing media:						
	Suitable extinguishing media:	conditions CO <sub>2</sub> , powder, or foam.  Large fire: Use water spray or alcohol resistant foam.  Treat as for vegetable oils.					
J.1.	Exunguishing media	Small fire: Use fire extinguishing methods suitable to surrounding					
5.1.	Extinguishing media	isul 63					
SECT	ION 5. Firefighting mea						
		, this should be symptomatic.					
		Quantities of up to 1500 mg of CBD per day are well tolerated by adults.  Acute toxicity is so low that it needs not to be classified accordingly.					
	prevent extended absorpti person should refrain from	abidiol contained is lipophilic and nearly not soluble in water. To fon of CBD in the digestive tract after oral uptake, the affected eating any fats or oils for at least 24 hours after ingestion.  In a contained in the digestive tract after oral uptake, the affected eating any fats or oils for at least 24 hours after ingestion.					
4.3.	Indication of any immediat	e medical attention and special treatment needed					
	Following ingestion:	Large amounts could cause nausea, vomiting, and irritation of the throat.					
	Following eye contact: There may be redness, discomfort, watering.						
	Following skin contact:	On long-term exposition there may be redness, itching, rash.					
	Following inhalation:	Cough, shortness of breath.					
4.2.	Most important symptoms	and effects, both acute and delayed					
	In case larger amounts of product vapours should have protect yourself with a particle-filtering face mask. contaminated clothes after first aid and wash with particle water and liquid soap.						
	Following ingestion:	Rinse mouth and throat with plenty of water. Drink plenty of water. If person feels unwell seek medical advice immediately and provide this Safety Data Sheet.					
	Following eye contact:	Rinse eyes with water. If irritation persists, seek medical attention.					
	Following skin contact:	In case of exposure of clothes to product, remove contaminated clothes. Wash affected area with soap and water. If irritation or rash develops, seek medical attention.					
	Following inhalation:	If symptoms of overexposure are experienced, move to fresh air. Rinse mouth and throat with plenty of water. Provide medical treatment if irritation, dyspnoea/shortness of breath or other symptoms should persist.					

Version 1



Product name:



Product code: CBD-OIL-25-NAT-MCT



5.3.	Advice for firefighters				
		apparatus for firefighting and full protective gear if necessary.			
5.4.	Additional information				
	No data available.				
SECTI	ON 6. Accidental release r	neasures			
6.1.		re equipment and emergency procedures			
6.1.1.	For non-emergency personnel				
	Protective equipment:	For personal protection see SECTION 8			
	Accident prevention methods:	No special measures, spill area may be slippery.			
	Emergency procedures:	Avoid inhaling vapours of the melt and provide adequate ventilation (e.g. local exhaust ventilation).			
6.2.	Environmental precautions				
	See SECTION 12 for additional	Ecological Information.			
6.3.	Methods and material for conta	ainment and cleaning up			
	Keep in suitable, closed contair	ners for disposal			
6.3.1.	Bonding, covering of drains; capping procedures:	nroduct should be covered with sultable inon-tiammable)			
6.3.2.	Cleaning up:	Collected material should be disposed of in accordance with locally valid regulations.  After removal of the spilled product use plenty of water and soap for emulsification.			
6.3.3.	Other information:	Upon escape of large amounts of product inform the Fire Department and the Environmental Department of the Municipal Authority.			
6.4.	Reference to other sections				
	See SECTION 13 for Disposal.				
SECTI	ON 7. Handling and storag	ge			
7.1.	Precautions for safe handling				
7.1.1.	Protective measures				
	Provide appropriate exhaust ve	entilation at storage and at the workplace.			
	Avoid contact with eyes, skin and clothing, do not inhale. Wear appropriate protective equipment. During work do not eat, drink or smoke.				
	Normal measures for preventat	ive fire protection.			
7.1.2.	Advice on general occupational	hygiene			
	Handle in accordance with goo	d industrial, hygiene and safety practice.			
7.2.	Conditions for safe storage, inc	luding any incompatibilities			

Version 1





Product code: CBD-OIL-25-NAT-MCT

	Technical measures and storage conditions:	not exceeding 30 °C. Protect the mixture against direct sun light and heat.			
	Packaging materials:	Containers made of glass, high density polyethylene (HDPE), polypropylene (PP), polyamide (PA), polytetrafluoroethylene (PTFE), ceramics, stainless steel, or aluminium with wide opening and tight seals. Use compatible packaging materials throughout for the uses, also fulfils the requirements for packaging of cosmetic end products. To avoid migration of undesired substances from the (plastics) packaging into the mixture, food compatible packaging material should be chosen.			
	Advices for storage equipment:	None			
	Further information on storage conditions:	Keep away from heat/sparks/open flames/ hot surfaces – no smoking.  Avoid contact with strong bases (alkaline substances) and with strong acids.			
7.3.	<u> </u>				
Recommendations:		Use in accordance with good manufacturing and industrial hygiene practices.			
SECTIO	ON 8. Exposure controls/p	ersonal protection			
8.1.	Control parameters				
8.1.1.	Occupational exposure limits:	There are no established occupational exposure limits for the mixture or the main constituent Cannabidiol.			
8.1.2.	DNEL/PNEC-values:	There are no established values for the products with Cannabidiol (CBD).  A No Observed Effect Level (NOEL) for Cannabidiol could be derived as ≥ 0.32 mg CBD oral / kg body mass from a human preclinical study			
8.2.	Exposure controls				
8.2.1.	Appropriate engineering cont	rols			
Avoid inhaling vapours of the m ventilation).		melt and provide adequate ventilation (e.g. local exhaust			
8.2.2. Personal protection equipment		nt			
8.2.2.1. Eye and face protection:		Wear standard safety glasses.			
8.2.2.2. Skin and hand protection:		In case of contact, wear suitable gloves. Change gloves in accordance with manufacturer's recommendations. If gloves are damaged during use, remove immediately and wash hands before replacing with new gloves. Laboratory coat or coverall should be worn to avoid skin contact.			

Version 1



Product name: 25% Natural CBD+CBDA in MCT

Product code: CBD-OIL-25-NAT-MCT



8.2.2.3.	Body protection:	The type of protective equipment according to the concentration and at the specific workplace.					
8.2.2.3. Respiratory protection:		mixture with efficient local exhau	Respiratory protection not required for handling of the mixture with efficient local exhaust ventilation. In a poorly ventilated environment wear respiratory mask for handling of the melt				
8.2.2.4.	Thermal hazards:	None					
8.2.3.	Environmental exposure	e controls					
	Prevent product run-off	to surface water or drains.					
	_	ers or absorption fluids of ventilation or le for disposal of contents / containers f or only.					
SECTI	ON 9. Physical and che	emical properties					
9.1.	Information on basic physi	cal and chemical properties					
	Parameter	Value	Remark				
	Appearance/form:	Thick, viscous liquid					
	Colour:	Dark yellow/ light brown liquid					
	Odour:	Flower odour / nutty, bitter taste					
	pH:	No data available					
	Melting point / freezing point;	No data available					
	Initial boiling point and boiling range:	Will degrade > 100 °C	experimental				
	Flash point:	> 200 °C	experimental				
	Evaporation rate:	No data available					
	Flammability (solid, gas):	No data available					
	Upper/lower flammability or explosive limits:	No data available					
	Vapour pressure:	< 0,1 mbar at 150 °C	experimental				
	Vapour density:	No data available					
	Relative density	< 0.95 based on oil	experimental				
	Bulk density:	No data available					
	Solubility(ies):	< 10 mg/l based on oil	estimated				
	Partition coefficient: n- octanol/water (log Kow):	No data available					
	Auto-ignition temperature:	No data available					



Product name: 25% Natural CBD+CBDA in MCT

Product code: CBD-OIL-25-NAT-MCT

	Decomposition temperature:	> 200°C			estimated			
	Viscosity:	at 20 °C, 25	5 – 33 mPa	s,	estimated			
	Explosive properties:	Not classifi	ed as explo					
	Oxidising properties:	Not classifi	ed as oxidis	ing				
9.2.	Other information							
	Practically insoluble in wa	ter, soluble in	Ethanol, M	lethanol, veg	etable fats.			
SECTI	ON 10.: Stability and r	reactivity						
10.1.	Reactivity		In strongly basic media and the presence of air, Cannabidiol (CBD) is oxidized to a quinone. With strong acids it reacts to give a complex mixture of cannabinoids.					
10.2.	Chemical stability		Stable un	der recomme	ended storage conditions.			
10.3.	Possibility of hazardous re	eactions	Hazardous polymerisation will not occur. Avoid contact with incompatible materials (see SECTION 10.5).					
10.4.	Conditions to avoid		Light, heat, moisture.					
10.5.	Incompatible materials		Strong oxidizing agents.					
			Strong reducing agents.					
			Strong ba	se, strong ac	id.			
10.6.	Hazardous decomposition	products	None kno	wn.				
SECTI	ON 11. Toxicological i	nformatio	n					
11.1.	Information on toxicologic	cal effects						
	Studies in animals indicate that a large portion of the administered CBD is excreted intact or as its glucuronide. Due to extensive Phase I metabolism, the pharmacokinetics of CBD is complex, and the bioavailability of oral CBD is low across species.  The most abundant metabolites are hydroxylated 7-COOH-derivatives of CBD that are excreted either intact or as glucuronide conjugates.							
11.2.	Acute toxicity							
	There are no data availabl	e on acute or	al toxicity f	or this mixtu	re.			
			, -					
	Data on acute oral toxicity for main constituent Cannabidiol (animal test):							
Stu	idy ID Species	Use dos		osure time	Results			

Version 1





Product code: CBD-OIL-25-NAT-MCT

	X150 BioA	CD1 Mice/12	0-300 mg/kg/day	13-week	The NOAEL was 400 mg/kg/day for male (Cmax AUC value of 6420 ng/mL and 37800 ng h/mL) and 550 mg/kg/day for female (Cmax AUC value of 8440 ng/mL and 41200 ng h/mL).			
	X150 BioA	Wistar Rat/10	0-150 mg/kg/day	26-week + 4 weeks recovery	The NOAEL of 150 mg/kg/day for male (Cmax AUC value of 6160 ng/mL and 60000 ng /mL) and for female (Cmax AUC value of 7530 ng/mL and 67500 ng h/mL).			
	X150 BioA	Beagle dogs/4- 6	0-100 mg/kg/day	39-week+ 4 weeks recovery	The NOAEL of 100 mg/kg/day for male (Cmax AUC value 20500 ng /mL) and for female (Cmax AUC value of 22400 ng h/mL).			
	EMA, Epi	dyolex, EMEA/H/C/0	004675/0000, 20	19.				
11.2.1.		ent/Classification						
11.3.		ture does not meet	the criteria for a	acute toxicity.				
11.3.		n and corrosion e mild skin irritation	hut not classif	ied as irritant				
	Iviay giv	e mila skin irritation	i, but not classii	ica as irritant.				
11.3.1.	Assessm	ent/Classification						
	Classific	ation criteria are no	ot met.					
11.4.	Sorious	eye damage / irritat	tion					
11.4.		mildly irritant to the		assified as irritant.				
	,	,	7 - ,					
11.4.1.	Assessm	ent/Classification						
	Based or	n available data, the	e classification c	riteria are not met.				
11.5.	Pospirat	ory or skin sensitisa	ation					
11.3.	•	•		on to the skin of so	me individuals			
	i idile ex	produce t	and Sic reacti					
11.5.1.	Assessm	ent/Classification						
	Based o	n available data, the	e classification c	riteria are not met.				
11.6.	CMR effects (carcinogenicity; mutagenicity; reproductive toxicity)							
		y of evaluation of t		•				
	There is	no data available o	n CMR effects o	of product.				





Product code: CBD-OIL-25-NAT-MCT

	There is data available for a Cannabis sativa extract with a higher content in CBD (a biological drug substance containing 69% of Cannabidiol): with that substance four genotoxicity assays have been conducted: AMES test (bacterial mutation assay), mouse mammalian cell mutation assay (mouse lymphoma), the mouse micronucleus assay, and the unscheduled DNA synthesis assay, which all produced negative results. At the concentrations tested, there were no genotoxic effects.  (Product Monograph Sativex®, GW Pharma Ltd., Cambridge, UK, Control N: 149598, date of Revision: March 31, 2015).
11.6.1.	Carcinogenicity
	There are no reports on carcinogenic effects of the product. A biological substance (Cannabis sativa extract) containing 69% of Cannabidiol was evaluated in a 2-year carcinogenicity study in rats ( <i>GW Study No JJG003</i> ) with 15 and 50 mg/kg/d. There was no indication of carcinogenic potential.
11.6.2.	Mutagenicity
	Cannabidiol was evaluated in a range of in vitro and in vivo standard genotoxicity assays.

In vitro mutagenicity / genotoxicity of Cannabidiol:

Cell type / Organism	Genetic Endpoint	Result / Evaluation	Remark
Fischer rat embryo (RLV/1706) cells	Cell transformation, viral enhanced (CTR-)	negative	Genetox Record No: 3129
Mammalian polychromatic erythrocytes	Micronucleus test, chromosome aberrations (MNT+)	positive	Genetox Record No: 3129
Human lymphocytes	Sister chromatid exchange (SCE) in vivo (SCY+)	positive	Genetox Record No: 3129


In vivo mutagenicity / genotoxicity of Cannabidiol:

Effect dose/- concen tration	Value	Cell type/ Organism	Genetic Endpoint	Result/ Evaluation	Remark			
n.a.	n.a.	Male mouse	Sperm morphology (SPI-)	negative	Genetox Record No: 3129			
	The genotoxic potential of CBD has been evaluated in a standard test battery of in vitro and in vivo assays according to ICH S2(R1). All tests concluded CBD to be negative for genotoxic potential.							
11.6.3.	Reproductive t	Reproductive toxicity						
	There is no data available on reproductive toxicity effects of this mixture.							
	Animal data on the main constituent Cannabidiol (CBD): Adverse effects of Cannabidiol on sexual function and fertility:							

Version 1



Product name:



Product code: CBD-OIL-25-NAT-MCT



Study type/ Study ID	Species; number group	Route & dose	Dosing period	Major findings	NOAEL (mg/kg)								
Male fertility GWTX1456/GLP	Wistar rat /20	75-250 mg/kg/day	2 weeks prior to pairing up to review of female pregnancy data	No effects on male reproductive organ weights	250 mg/kg/day								
Female fertility GWTX1456/GLP	Wistar rat /20	75-250 mg/kg/day	2 weeks prior to pairing up to GD 6	No effect on female reproductive indices, female oestrus cycling or pregnancy parameters	250 mg/kg/day								
Embryo-foetal development GWTX1455/non GLP	Wistar/6 DRF study	150-300 mg/kg/day	GD6 to 17	300 mg/kg/day: One dead rat, weight loss of 32% of controls. Increased preimplantation loss at 300 mg/kg/day. No adverse effects at lower doses	F0:250 mg/kg/day F1:250 mg/kg/day								
Embryo-foetal development GWTX1454/GLP Bioanalysis & TK: non-GLP	Wistar /20	75-250 mg/kg/day	GD6 to 17	Complete litter loss of 2/20 dams at 250 mg/kg/day	F0:150 mg/kg/day F1:150 mg/kg/day								
Embryo-foetal development DRF GWTX1453/ Non-GLP	Rabbit/6	50-125 mg/kg/day	GD7 to 19	Body weight loss compared to controls	DRF study NA								
Embryo- foetal development DRF GWTX1452/ GLP	Rabbit /22	50-125 mg/kg/day	GD7 to 19	Unossified metacarpal, bulging eyes, and nonerupted incisors) were considered to be secondary to the reduced fatal weights at 125 mg/kg/day.	F0:80 mg/kg/day F1:80 mg/kg/day								
Pre & postnatal development GWTX1532/GLP	Rat/22	75-250 mg/kg/day	GD6 to LD21	F1 males: Small testes F1 female: Reduced fertility indices	F0:250 mg/kg/day F1:75 mg/kg/day								
EMA, Epidyolex,	EMEA/H/C/0046	75/0000, 20	19.	1	J. J/								
	Assessment / Classification  No human data on the effect of CRD on fortility are available. No effect on reproductive												
l :	No human data on the effect of CBD on fertility are available. No effect on reproductive ability of male or female rats was noted with an oral dose of up to 150 mg/kg/day CBD												
11.6.4. Specific	target toxicity -	single exposi	ure (STOT SE1 and	d 2)									
		THISIC CAPOSI	(3. 3. 1 3L1 am										
CDD III	aacco nver mjury				CBD induces liver injury								

Version 1





Product code: CBD-OIL-25-NAT-MCT

	Liver toxicity has been systematically monitored and may occur. These toxicity appear to be		
	due to a direct hepatocellular effect of CBD-OS or its metabolites.  Committee on toxicity of chemicals in food, consumer products and the environment TOX/2020/02		
11.6.5.	Narcotic effects		
	CBD is not listed in the Single Convention on Narcotic Drugs, UN, 1961, as amended. CBD does not exert narcotic effects.		
	Assessment / Classification		
	The product does not have narcotic effects.		
11.6.6.	Aspiration hazard		
	Practical experience / human evidence: No data available		
	Assessment / Classification		
	Based on available data, the classification criteria are not met.		
11.2.	Practical experiences		
	Classification observations: No information available		
	Other observations:		
11.3.	General notes		
SECTIO	ON 12. Ecological information		
12.1.	Toxicity		
	Aquatic toxicity		
	There is no experimental data on short-term or long-term aquatic toxicity of the mixture.		
	The main constituent Cannabidiol is nearly insoluble in water, this also applies to the glycerides (fats) present in the mixture. Therefore, accumulation by dissolution in surface waters is not probable.		
	Assessment / Classification:		
	No classification no data available		
12.2.	Persistence and degradability		
	There is no experimental data on persistence or biodegradability.		

Version 1





25% Natural CBD+CBDA in MCT Product name:

Product code: CBD-OIL-25-NAT-MCT

	The product is composed of naturally occurring plant oils and is expected to be ultimately biodegradable.
12.3.	Bio accumulative potential
	There is no experimental data on bioaccumulative potential.
12.4.	Mobility in soil
	There are no experimental data on mobility in soil.
12.5.	Results of PBT and vPvB assessment
	Not required (for Chemical Safety Report only). This product does not meet the PBT/vPvB criteria of REACH, Annex XIII.
12.6.	Other adverse effects
	No data available

SECTION 13. Disposal considerations				
13.1.	Waste treatment methods			
	Recovery and recycling are no regulations.	ot possible. Incinerate or dispose of in accordance with local		
13.1.1.	Product/Packaging disposal			
	Dispose of packaging materi regulations.	al as low-hazard packaging waste within scope of local		
13.1.2.	Other disposal recommendations			
	Do not empty unused product into drainage systems.			
	The product must not be disposed of with municipal waste.			
	Empty containers must be used at waste incinerators (plastic) to produce energy or deposited in a dump with appropriate classification.			
	Perfectly cleaned containers may be submitted for recycling.			
SECTIO	N 14. Transport informa	tion		
	Transporting/shipment			
14.1	UN number:			
	AND	None		
	ADR/RID	None		

Version 1



Product name: 25% Natural CBD+CBDA in MCT

Product code: CBD-OIL-25-NAT-MCT

	ICAO-TI/IATA-DGR	None		
	IMDG	None		
14.2	UN proper shipping name:			
	AND	Not dangerous goods		
	ADR/RID	Not dangerous goods		
	ICAO-TI/IATA-DGR	Not dangerous goods		
	IMDG	Not dangerous goods		
14.3	Tuescop sub-based alass/selv			
14.3	Transport hazard class(es):  AND	None		
	ADR/RID	None		
	ICAO-TI/IATA-DGR	None		
	IMDG	None		
14.4	Packing group:			
	AND	None		
	ADR/RID	None		
	ICAO-TI/IATA-DGR	None		
	IMDG	None		
14.5	Environmental hazards:			
	AND	None		
	ADR/RID	None		
	ICAO-TI/IATA-DGR	None		
	IMDG	None		
14.6	Special precautions for user:			
14.0	Not dangerous goods in the meaning of transport regulation			
	Not dangerous goods in the h	nearing of transport regulation		
Further	information: Store, cooled, at	dry and dark place.		
	Protect from dir	ect light and heat.		
	Keep out of read	ch of young children.		
	The product sho closed and clean	e transported in well closed containers or drums in ८९.		
SECTI	ON 15. Regulatory inform	ation		





Product code: CBD-OIL-25-NAT-MCT

15.1.	Safety, health, and environmental regulations/legislation specific for the substance or mixture					
	Authorisations: Not required for professional use.					
	Restrictions on use: None under professional use					
	Restrictions of occupation: None					
15.2.	,					
	A Chemical Safety Assessment under the EU REACH Regulation is not required for this product.					
16.1	ON 16. Other inf					
10.1	Indication of chang					
	This safety data sh	eet is the original version 2.0, dated 01. April, 2021.				
16.2	Abbreviations and	d acronyms				
	ADR	European Agreement concerning the International Carriage of Dangerous Goods by Road				
	CAS	Chemical Abstracts Service				
	CLP	Classification, Labelling, Packaging				
	DNEL	Derived No Effect Level				
	EC	European Community				
	EU	European Union				
	IATA-DGR	International Air Transport Association - Dangerous Goods Regulations				
	ICAO-TI	International Civil Aviation Organization - Technical Instructions				
	IMDG	Code International Maritime Code for Dangerous Goods				
	LC	Lethal concentration				
	LD	Lethal dose				
	log KOW	Octanol-water partition coefficient				
	NOAEL No	Observed Adverse Effect Level				
	PBT	Persistent, Bioaccumulative, and Toxic				
	PNEC	Predicted No Effect Concentration				
	REACH	Registration, Evaluation, and Authorisation of Chemicals				
	vPvB	very Persistent and very Bioaccumulative				
	STOT	Specific Target Organ Toxicity (SE = Single Exposure, RE = Repeated Exposure)				



Product name: 25% Natural CBD+CBDA in MCT

Product code: CBD-OIL-25-NAT-MCT



UVCB	Substances of unknown or variable composition, complex reaction products or biological
VOC	Volatile Organic Compounds

#### ANNEX: Exposure scenario resulting to Chemical safety assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information, and belief at the date of its publication. The information given is designed as a guidance for safe handling, use, processing, storage, transportation, disposal, and release and is not to be considered a warranty or quality specification. The information in this document are applicable to the product regarding appropriate safety precautions. It does not represent any guarantee of properties of the product.

This information must be made available to those who may encounter the material or are responsible for the use of the material. This Safety Data Sheet is prepared in accordance with formatting described in the REACH Regulation (EC) No 1907/2006 and described in CLP Regulation (EC) No 1272/2008.

#### \*Further information:

Copyright 2021. License granted to make unlimited paper copies for internal use only.

CBD Oil Europe and its Affiliates shall not be held liable for any damage resulting from handling or from contact with the above product.

Version 1